Home > Newsletters > Clinical Trials Advisor > Bapineuzumab Failure May Signal Bleak Outlook for Alzheimer’s Drugs
Clinical Trials Advisor
Aug. 16, 2012 | Vol. 17 No. 16
Bapineuzumab Failure May Signal Bleak Outlook for Alzheimer’s Drugs
Pfizer, Johnson & Johnson (J&J) and Elan’s termination of their late-stage program for investigational Alzheimer’s drug bapineuzumab following the second failed study may not negatively impact the companies but could foreshadow a bleak outlook for the future of Alzheimer’s drug development, analysts say.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.